Develops antibody medicines for menopause and dermatitis.
Jun 2026Revenue $66.2M/yrExpenses $291M/yr
No trendCash runway ≈ 1.0 years from Jun 2026
Figures by year
When will AbCellera Biologics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $66.2M and expenses $291M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $75.1M | $292M | −$217M |
| Dec 2024 | $28.8M | $344M | −$315M |
| Dec 2023 | $38.0M | $275M | −$237M |
| Dec 2022 | $485M | $269M | $217M |
| Dec 2021 | $375M | $171M | $204M |
| Dec 2020 | $233M | $77.1M | $156M |
| Dec 2019 | $11.6M | $15.7M | −$4.12M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.